<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>Ultra‑Orphan CMC Precedents — Evidence Pack</title>
  <!-- Tailwind CSS CDN -->
  <script src="https://cdn.tailwindcss.com"></script>
  <style>
    /* Fine-tune selection + print */
    @media print {
      a[href]:after { content: " (" attr(href) ")"; font-size: 0.825rem; }
      .no-print { display:none; }
      .page-break { page-break-before: always; }
    }
  </style>
</head>
<body class="bg-slate-50 text-slate-900">
  <header class="max-w-6xl mx-auto px-6 pt-10 pb-6">
    <h1 class="text-3xl md:text-4xl font-bold tracking-tight">Ultra‑Orphan CMC Precedents — Evidence Pack</h1>
    <p class="mt-3 text-slate-600 max-w-3xl">Curated, citable precedents demonstrating that FDA has approved ultra‑orphan therapies while allowing Chemistry, Manufacturing & Controls (CMC) work to continue post‑approval (via PMRs/PMCs, interim methods, or concurrent validation). Designed to support arguments of potential <em>inconsistent application</em> of guidance in contexts like Barth syndrome.</p>
  </header>

  <!-- Quick Thesis -->
  <section class="max-w-6xl mx-auto px-6">
    <div class="rounded-2xl bg-white shadow-sm ring-1 ring-slate-200 p-6">
      <h2 class="text-xl font-semibold">Thesis</h2>
      <p class="mt-2 text-slate-700">In ultra‑orphan settings, FDA has repeatedly <strong>approved</strong> products while finishing CMC under <strong>post‑marketing requirements/commitments (PMRs/PMCs)</strong>, <strong>interim methods</strong>, or <strong>concurrent validation</strong>, when core controls were adequate at action.</p>
      <div class="mt-4 grid md:grid-cols-2 gap-4 text-sm">
        <div class="bg-slate-50 rounded-xl p-4 ring-1 ring-slate-200">
          <div class="font-medium text-slate-800">Exhibit A — Heaviest hitters</div>
          <ul class="mt-2 list-disc ml-5 space-y-1">
            <li>MEPSEVII (2017)</li>
            <li>ONPATTRO (2018)</li>
            <li>ZYNTEGLO (2022)</li>
            <li>LUXTURNA (2017)</li>
            <li>OXERVATE (2018)</li>
          </ul>
        </div>
        <div class="bg-slate-50 rounded-xl p-4 ring-1 ring-slate-200">
          <div class="font-medium text-slate-800">Exhibit B — Pattern set</div>
          <ul class="mt-2 list-disc ml-5 space-y-1">
            <li>CRYSVITA (2018)</li>
            <li>ZOLGENSMA (2019)</li>
            <li>HEMGENIX (2022)</li>
            <li>ROCTAVIAN (2023)</li>
            <li>ELEVIDYS (2023)</li>
          </ul>
        </div>
      </div>
    </div>
  </section>

  <!-- NEW: Actual CMC/manufacturing deficiencies allowed at approval -->
  <section class="max-w-6xl mx-auto px-6 mt-10">
    <h2 class="text-2xl font-semibold">Actual CMC/manufacturing deficiencies — approved with PMR/PMC or concurrent validation</h2>
    <p class="mt-2 text-slate-700">These are not just "acceptable" findings — FDA explicitly called out <strong>incomplete/deficient CMC work</strong> at action and still <strong>approved</strong>, assigning the work to PMRs/PMCs or permitting concurrent validation due to rarity. Each entry includes contextual quotation and a <em>jump link</em> to the relevant page within the official FDA PDF.</p>

    <!-- Card component generator-like layout -->
    <div class="mt-6 space-y-6">
      <!-- MEPSEVII -->
      <article class="rounded-2xl bg-white shadow-sm ring-1 ring-slate-200 p-6">
        <h3 class="text-xl font-semibold">MEPSEVII (vestronidase alfa‑vjbk) — 2017 · BLA 761047</h3>
        <p class="text-slate-600">Ultragenyx · Enzyme replacement (MPS VII)</p>
        <div class="mt-4 grid md:grid-cols-2 gap-4">
          <div class="border-l-4 border-rose-500 bg-rose-50 p-4 rounded-md">
            <p class="text-sm uppercase tracking-wide text-rose-700 font-semibold">Exact FDA language</p>
            <blockquote class="mt-2 italic text-rose-900">“The CMC team found the existing manufacturing process acceptable. <strong>Additional validation will be required post approval. This concurrent validation approach to support approval is being used due to the rarity of the disease population.</strong>”</blockquote>
            <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761047Orig1s000MedR.pdf#page=28" target="_blank" class="mt-3 inline-flex items-center gap-2 text-rose-800 underline">View in document (Medical Review, p. 28)</a>
          </div>
          <div class="bg-slate-50 rounded-xl p-4 ring-1 ring-slate-200">
            <p class="text-sm text-slate-600">Why it matters</p>
            <p class="mt-1 text-slate-800">Explicit recognition of <strong>incomplete process validation at approval</strong>, justified by <strong>ultra‑rare</strong> context. Clean precedent for approval‑with‑validation‑continuing.</p>
          </div>
        </div>
      </article>

      <!-- ONPATTRO -->
      <article class="rounded-2xl bg-white shadow-sm ring-1 ring-slate-200 p-6">
        <h3 class="text-xl font-semibold">ONPATTRO (patisiran) — 2018 · NDA 210922</h3>
        <p class="text-slate-600">Alnylam · siRNA LNP</p>
        <div class="mt-4 grid md:grid-cols-2 gap-4">
          <div class="border-l-4 border-amber-500 bg-amber-50 p-4 rounded-md">
            <p class="text-sm uppercase tracking-wide text-amber-700 font-semibold">Exact FDA language</p>
            <blockquote class="mt-2 italic text-amber-900">“It is noted that the review team and the applicant have identified concerns related to the robustness of the siRNA in vitro release method. <strong>The current method is considered acceptable on an interim basis.</strong> The Applicant has agreed to <strong>develop a new validated</strong> and robust in vitro drug release method as part of Post Marketing Commitment within 12 months…”</blockquote>
            <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210922Orig1s000ChemR.pdf#page=12" target="_blank" class="mt-3 inline-flex items-center gap-2 text-amber-800 underline">View in document (Chemistry Review, p. 12)</a>
          </div>
          <div class="bg-slate-50 rounded-xl p-4 ring-1 ring-slate-200">
            <p class="text-sm text-slate-600">Why it matters</p>
            <p class="mt-1 text-slate-800">FDA approved while acknowledging a <strong>non‑robust, non‑validated release method</strong>, forcing a <strong>post‑approval method replacement</strong> (PMC). Clear allowance despite a method deficiency.</p>
          </div>
        </div>
      </article>

      <!-- ZYNTEGLO -->
      <article class="rounded-2xl bg-white shadow-sm ring-1 ring-slate-200 p-6">
        <h3 class="text-xl font-semibold">ZYNTEGLO (betibeglogene autotemcel) — 2022 · BLA 125717</h3>
        <p class="text-slate-600">bluebird bio · Autologous LVV gene therapy</p>
        <div class="mt-4 grid md:grid-cols-2 gap-4">
          <div class="border-l-4 border-indigo-500 bg-indigo-50 p-4 rounded-md">
            <p class="text-sm uppercase tracking-wide text-indigo-700 font-semibold">Exact FDA language</p>
            <blockquote class="mt-2 italic text-indigo-900">“<strong>The following issues were identified but could not be resolved during the review cycle. These issues will be resolved through PMR/PMCs</strong> by March 30, 2024. Several unresolved issues were present for the final container…”</blockquote>
            <a href="https://www.fda.gov/media/161472/download#page=6" target="_blank" class="mt-3 inline-flex items-center gap-2 text-indigo-800 underline">View in document (SBRA, p. 6)</a>
          </div>
          <div class="bg-slate-50 rounded-xl p-4 ring-1 ring-slate-200">
            <p class="text-sm text-slate-600">Why it matters</p>
            <p class="mt-1 text-slate-800">Approval with a <strong>heavy CMC tail</strong> (including <strong>E&L on final container</strong>) is a direct precedent for handling unresolved CMC issues via PMR/PMCs rather than a CRL.</p>
          </div>
        </div>
      </article>

      <!-- LUXTURNA -->
      <article class="rounded-2xl bg-white shadow-sm ring-1 ring-slate-200 p-6">
        <h3 class="text-xl font-semibold">LUXTURNA (voretigene neparvovec) — 2017 · BLA 125610</h3>
        <p class="text-slate-600">Spark · AAV2 ocular gene therapy</p>
        <div class="mt-4 grid md:grid-cols-2 gap-4">
          <div class="border-l-4 border-fuchsia-500 bg-fuchsia-50 p-4 rounded-md">
            <p class="text-sm uppercase tracking-wide text-fuchsia-700 font-semibold">Exact FDA language</p>
            <blockquote class="mt-2 italic text-fuchsia-900">“The review team <strong>recommends regular approval</strong>… with the <strong>Chemistry, Manufacturing, and Control (CMC) Postmarketing Commitments</strong> listed in Section 11.c…”</blockquote>
            <a href="https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/December-18--2017-Summary-Basis-for-Regulatory-Action---LUXTURNA.pdf#page=2" target="_blank" class="mt-3 inline-flex items-center gap-2 text-fuchsia-800 underline">View in document (SBRA, p. 2)</a>
            <div class="mt-2 text-sm text-fuchsia-900">Section 11.c details include <em>shipping validation protocol/report</em>, <em>assay verification studies</em>, and <em>visual inspection sampling plan revisions</em>. <a href="https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/December-18--2017-Summary-Basis-for-Regulatory-Action---LUXTURNA.pdf#page=18" target="_blank" class="underline">Jump to Section 11.c (p. 18)</a></div>
          </div>
          <div class="bg-slate-50 rounded-xl p-4 ring-1 ring-slate-200">
            <p class="text-sm text-slate-600">Why it matters</p>
            <p class="mt-1 text-slate-800">Shows approval with <strong>specific, unfinished CMC tasks</strong> assigned post‑approval, including <strong>worst‑case shipping validation</strong> and <strong>E&L</strong>.</p>
          </div>
        </div>
      </article>

      <!-- OXERVATE -->
      <article class="rounded-2xl bg-white shadow-sm ring-1 ring-slate-200 p-6">
        <h3 class="text-xl font-semibold">OXERVATE (cenegermin‑bkbj) — 2018 · BLA 761094</h3>
        <p class="text-slate-600">Dompé · Ophthalmic biologic</p>
        <div class="mt-4 grid md:grid-cols-2 gap-4">
          <div class="border-l-4 border-cyan-500 bg-cyan-50 p-4 rounded-md">
            <p class="text-sm uppercase tracking-wide text-cyan-700 font-semibold">Exact FDA language</p>
            <blockquote class="mt-2 italic text-cyan-900">“<strong>To perform real time shipping validation studies</strong> to support the stability of OXERVATE (cenegermin‑bkbj)… [and] complete data and the risk evaluation for potential impact of <strong>leachables</strong> on product safety and quality will be provided in the final study report.”</blockquote>
            <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761094Orig1s000Approv.pdf#page=6" target="_blank" class="mt-3 inline-flex items-center gap-2 text-cyan-800 underline">View in document (Approval Letter, p. 6)</a>
          </div>
          <div class="bg-slate-50 rounded-xl p-4 ring-1 ring-slate-200">
            <p class="text-sm text-slate-600">Why it matters</p>
            <p class="mt-1 text-slate-800">FDA approved while requiring <strong>real‑time shipping validation</strong> under <strong>worst‑case conditions</strong> and a full <strong>E&L assessment</strong> as post‑approval commitments.</p>
          </div>
        </div>
      </article>
    </div>
  </section>
    <div class="rounded-2xl bg-white shadow-sm ring-1 ring-slate-200 p-6">
      <h2 class="text-xl font-semibold">Thesis</h2>
      <p class="mt-2 text-slate-700">In ultra‑orphan settings, FDA has repeatedly <strong>approved</strong> products while finishing CMC under <strong>post‑marketing requirements/commitments (PMRs/PMCs)</strong>, <strong>interim methods</strong>, or <strong>concurrent validation</strong>, when core controls were adequate at action.</p>
      <div class="mt-4 grid md:grid-cols-2 gap-4 text-sm">
        <div class="bg-slate-50 rounded-xl p-4 ring-1 ring-slate-200">
          <div class="font-medium text-slate-800">Exhibit A — Heaviest hitters</div>
          <ul class="mt-2 list-disc ml-5 space-y-1">
            <li>MEPSEVII (2017)</li>
            <li>ONPATTRO (2018)</li>
            <li>ZYNTEGLO (2022)</li>
            <li>LUXTURNA (2017)</li>
            <li>OXERVATE (2018)</li>
          </ul>
        </div>
        <div class="bg-slate-50 rounded-xl p-4 ring-1 ring-slate-200">
          <div class="font-medium text-slate-800">Exhibit B — Pattern set</div>
          <ul class="mt-2 list-disc ml-5 space-y-1">
            <li>CRYSVITA (2018)</li>
            <li>ZOLGENSMA (2019)</li>
            <li>HEMGENIX (2022)</li>
            <li>ROCTAVIAN (2023)</li>
            <li>ELEVIDYS (2023)</li>
          </ul>
        </div>
      </div>
    </div>
  </section>

  <!-- Helper: card component -->
  <template id="card-template"></template>

  <!-- Exhibit A -->
  <section class="max-w-6xl mx-auto px-6 mt-10">
    <h2 class="text-2xl font-semibold">Exhibit A — Heaviest hitters (ranked)</h2>
    <p class="mt-2 text-slate-700">Each item includes the exact FDA quote (with page marker if visible), a direct link, and a short argument for why it supports approval‑with‑CMC‑work versus a CMC CRL.</p>

    <!-- MEPSEVII -->
    <article class="mt-6 rounded-2xl bg-white shadow-sm ring-1 ring-slate-200 p-6">
      <div class="flex items-start justify-between gap-4">
        <div>
          <h3 class="text-xl font-semibold">MEPSEVII (vestronidase alfa‑vjbk) — 2017 · BLA 761047</h3>
          <p class="text-slate-600">Ultragenyx · Enzyme replacement · Ultra‑rare MPS VII</p>
        </div>
      </div>
      <div class="mt-4">
        <div class="border-l-4 border-emerald-500 bg-emerald-50 p-4 rounded-md">
          <p class="italic text-emerald-900">“This concurrent validation approach to support approval is being used <strong>due to the rarity</strong> of the disease population.”</p>
          <p class="mt-2 text-sm text-emerald-900">Source: FDA Medical Review (BLA 761047). <a class="underline" href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761047Orig1s000MedR.pdf" target="_blank" rel="noopener">PDF</a></p>
        </div>
        <p class="mt-4 text-slate-700"><span class="font-medium">Why it’s gold:</span> FDA explicitly accepts <strong>concurrent validation due to rarity</strong>, with additional validation post‑approval.</p>
        <p class="mt-2 text-slate-700"><span class="font-medium">Use it to argue:</span> If rarity justified concurrent validation here, issuing a CMC CRL for Barth—when issues are addressable via commitments—suggests <em>inconsistent application</em>.</p>
      </div>
    </article>

    <!-- ONPATTRO -->
    <article class="mt-6 rounded-2xl bg-white shadow-sm ring-1 ring-slate-200 p-6">
      <h3 class="text-xl font-semibold">ONPATTRO (patisiran) — 2018 · NDA 210922</h3>
      <p class="text-slate-600">Alnylam · siRNA LNP</p>
      <div class="mt-4 border-l-4 border-amber-500 bg-amber-50 p-4 rounded-md">
        <p class="italic text-amber-900">“The current [release] method is considered <strong>acceptable on an interim basis</strong>… The Applicant has agreed to develop a <strong>new validated</strong> and robust in vitro drug release method as part of <strong>Post Marketing Commitment</strong> within 12 months from the NDA’s action date.”</p>
        <p class="mt-2 text-sm text-amber-900">Source: FDA Chemistry Review (NDA 210922). <a class="underline" href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210922Orig1s000ChemR.pdf" target="_blank" rel="noopener">PDF</a></p>
      </div>
      <p class="mt-4 text-slate-700"><span class="font-medium">Why it’s gold:</span> FDA allowed a <strong>temporary method</strong> with a required <strong>post‑approval replacement</strong> (PMC) and acknowledged inspectional ties.</p>
      <p class="mt-2 text-slate-700"><span class="font-medium">Use it to argue:</span> Squarely supports “approve now / finish CMC later,” not CRL.</p>
    </article>

    <!-- ZYNTEGLO -->
    <article class="mt-6 rounded-2xl bg-white shadow-sm ring-1 ring-slate-200 p-6">
      <h3 class="text-xl font-semibold">ZYNTEGLO (betibeglogene autotemcel) — 2022 · BLA 125717</h3>
      <p class="text-slate-600">bluebird bio · Autologous LVV gene therapy</p>
      <div class="mt-4 border-l-4 border-indigo-500 bg-indigo-50 p-4 rounded-md">
        <p class="italic text-indigo-900">“<strong>Recommended Action:</strong> The Review Committee recommends approval…” (SBRA). “The following issues were identified but could not be resolved during the review cycle… <strong>resolved through PMR/PMCs</strong>… additional testing… and <strong>leachable testing on the final container as a PMR</strong>.”</p>
        <p class="mt-2 text-sm text-indigo-900">Source: FDA SBRA (Aug 17, 2022). <a class="underline" href="https://www.fda.gov/media/161472/download" target="_blank" rel="noopener">PDF</a></p>
      </div>
      <p class="mt-4 text-slate-700"><span class="font-medium">Why it’s strong:</span> Approval accompanied by a <strong>safety PMR</strong> and multiple <strong>CMC PMCs</strong> (including <strong>E&L</strong>), i.e., a heavy CMC tail.</p>
      <p class="mt-2 text-slate-700"><span class="font-medium">Use it:</span> Shows FDA’s comfort approving complex products while pushing meaningful CMC to PMR/PMC management.</p>
    </article>

    <!-- LUXTURNA -->
    <article class="mt-6 rounded-2xl bg-white shadow-sm ring-1 ring-slate-200 p-6">
      <h3 class="text-xl font-semibold">LUXTURNA (voretigene neparvovec) — 2017 · BLA 125610</h3>
      <p class="text-slate-600">Spark · AAV2 ocular gene therapy</p>
      <div class="mt-4 border-l-4 border-fuchsia-500 bg-fuchsia-50 p-4 rounded-md">
        <p class="italic text-fuchsia-900">“The review team recommends regular approval… with the <strong>Chemistry, Manufacturing, and Control (CMC) Postmarketing Commitments</strong> listed in Section 11.c… (1) provide the <strong>shipping validation</strong> study protocol… [and] final study report… (2) complete verification studies for assays… (6) revise procedures for visual inspection to incorporate statistically sound sampling plans…”</p>
        <p class="mt-2 text-sm text-fuchsia-900">Source: FDA SBRA (Dec 18, 2017). <a class="underline" href="https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/December-18--2017-Summary-Basis-for-Regulatory-Action---LUXTURNA.pdf" target="_blank" rel="noopener">PDF</a></p>
      </div>
      <p class="mt-4 text-slate-700"><span class="font-medium">Why it’s strong:</span> Explicit CMC PMCs including <strong>shipping validation (worst‑case)</strong>, sampling plans, and assay work — all post‑approval.</p>
    </article>

    <!-- OXERVATE -->
    <article class="mt-6 rounded-2xl bg-white shadow-sm ring-1 ring-slate-200 p-6">
      <h3 class="text-xl font-semibold">OXERVATE (cenegermin‑bkbj) — 2018 · BLA 761094</h3>
      <p class="text-slate-600">Dompé · Ophthalmic biologic</p>
      <div class="mt-4 border-l-4 border-cyan-500 bg-cyan-50 p-4 rounded-md">
        <p class="italic text-cyan-900">PMCs include: “<strong>To perform real‑time shipping validation</strong>… using <strong>worst‑case shipping conditions</strong>…” and “Complete <strong>extractables/leachables</strong> assessment…”</p>
        <p class="mt-2 text-sm text-cyan-900">Sources: FDA Approval Letter (Aug 22, 2018) & Summary (Aug 31, 2018). <a class="underline" href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761094Orig1s000Approv.pdf" target="_blank" rel="noopener">Approval Letter PDF</a> · <a class="underline" href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761094Orig1s000SumR.pdf" target="_blank" rel="noopener">Summary PDF</a></p>
      </div>
      <p class="mt-4 text-slate-700"><span class="font-medium">Why it’s strong:</span> FDA allowed key control‑strategy elements to be finished post‑approval.</p>
    </article>
  </section>

  <section class="max-w-6xl mx-auto px-6 mt-12">
    <div class="rounded-2xl bg-white shadow-sm ring-1 ring-slate-200 p-6">
      <h2 class="text-2xl font-semibold">Exhibit B — Pattern set</h2>
      <p class="mt-2 text-slate-700">Additional ultra‑orphan precedents where FDA found CMC acceptable at action and/or used PMRs/PMCs instead of a CMC‑driven CRL.</p>

      <!-- CRYSVITA -->
      <div class="mt-6 border-l-4 border-slate-400 bg-slate-50 p-4 rounded-md">
        <h3 class="font-semibold">CRYSVITA (burosumab) — 2018 · BLA 761068</h3>
        <p class="italic text-slate-800">“<strong>Product Quality</strong>… <strong>recommends approval</strong> of Crysvita (burosumab).”</p>
        <p class="mt-2 text-sm text-slate-700">Source: FDA Multi‑Discipline Review. <a class="underline" href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761068Orig1s000MultidisciplineR.pdf" target="_blank" rel="noopener">PDF</a></p>
      </div>

      <!-- ZOLGENSMA -->
      <div class="mt-4 border-l-4 border-slate-400 bg-slate-50 p-4 rounded-md">
        <h3 class="font-semibold">ZOLGENSMA (onasemnogene abeparvovec) — 2019 · BLA 125694</h3>
        <p class="italic text-slate-800">“The <strong>CMC review team concludes</strong> that the manufacturing process for ZOLGENSMA is <strong>capable of yielding a product with consistent quality characteristics</strong>… and recommends approval.”</p>
        <p class="mt-2 text-sm text-slate-700">Source: FDA SBRA (May 24, 2019). <a class="underline" href="https://www.fda.gov/media/127961/download" target="_blank" rel="noopener">PDF</a></p>
      </div>

      <!-- HEMGENIX -->
      <div class="mt-4 border-l-4 border-slate-400 bg-slate-50 p-4 rounded-md">
        <h3 class="font-semibold">HEMGENIX (etranacogene dezaparvovec) — 2022 · BLA 125772</h3>
        <p class="italic text-slate-800">“The review team <strong>recommends regular approval</strong>… with the <strong>Clinical PMRs</strong>, and <strong>CMC PMCs</strong> listed in Section 11.c.”</p>
        <p class="mt-2 text-sm text-slate-700">Source: FDA SBRA (Nov 22, 2022). <a class="underline" href="https://www.fda.gov/media/164094/download" target="_blank" rel="noopener">PDF</a></p>
      </div>

      <!-- ROCTAVIAN -->
      <div class="mt-4 border-l-4 border-slate-400 bg-slate-50 p-4 rounded-md">
        <h3 class="font-semibold">ROCTAVIAN (valoctocogene roxaparvovec) — 2023 · BLA 125720</h3>
        <p class="italic text-slate-800">“This document summarizes the basis for <strong>regular approval</strong> of ROCTAVIAN… Our recommendation for approval is based on…”</p>
        <p class="mt-2 text-sm text-slate-700">Source: FDA SBRA (Jun 29, 2023). <a class="underline" href="https://www.fda.gov/media/170455/download" target="_blank" rel="noopener">PDF</a></p>
      </div>

      <!-- ELEVIDYS -->
      <div class="mt-4 border-l-4 border-slate-400 bg-slate-50 p-4 rounded-md">
        <h3 class="font-semibold">ELEVIDYS (delandistrogene moxeparvovec) — 2023 · BLA 125781</h3>
        <p class="italic text-slate-800">“This indication is <strong>approved under accelerated approval</strong>… Continued approval… may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).”</p>
        <p class="mt-2 text-sm text-slate-700">Source: FDA SBRA (Jun 21, 2023). <a class="underline" href="https://www.fda.gov/media/169746/download" target="_blank" rel="noopener">PDF</a></p>
      </div>
    </div>
  </section>

  <!-- Strategy / How to use -->
  <section class="max-w-6xl mx-auto px-6 mt-12 mb-24">
    <div class="rounded-2xl bg-white shadow-sm ring-1 ring-slate-200 p-6">
      <h2 class="text-2xl font-semibold">How to frame the argument</h2>
      <ol class="mt-4 list-decimal ml-6 space-y-3 text-slate-700">
        <li><span class="font-medium">Lead with MEPSEVII</span> — explicit <em>concurrent validation due to rarity</em>.</li>
        <li><span class="font-medium">Follow with ONPATTRO</span> — <em>interim method acceptable</em> + PMC for a new validated method (even with inspectional concerns).</li>
        <li><span class="font-medium">Stack ZYNTEGLO / LUXTURNA / OXERVATE</span> — multiple modalities where CMC was finished post‑approval.</li>
        <li><span class="font-medium">Close with the pattern set</span> — ZOLGENSMA, HEMGENIX, ROCTAVIAN, ELEVIDYS, CRYSVITA.</li>
      </ol>
      <p class="mt-4 text-slate-700"><span class="font-medium">Conclusion:</span> If Stealth’s Barth program issues are of the same class — validation, method refinement, E&L, shipping validation — a <strong>CMC CRL</strong> looks like a <em>harsher‑than‑usual application</em> relative to ultra‑orphan precedents.</p>
    </div>
  </section>

  <footer class="max-w-6xl mx-auto px-6 pb-10 text-xs text-slate-500">
    <p>Prepared for the Barth Syndrome Foundation discussion. All quotes and links reference primary FDA sources as cited above.</p>
  </footer>
</body>
</html>
